Title: Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the
treatment of chronic hepatitis C: the real-world data in China
Version: 0 Date: 03 Jul 2023
Reviewer's report:
This study investigated head-to-head comparison between a well-established DAA HCV
treatment represented by Epclusa vs a newly approved Chinese DAA called Danoprevir. The
authors compared two groups of patients treated with both treatment regimens. There are couple
of issues needs to be addressed:
1- The mode of action of Danoprevir needs to be added in the introduction.
2- The SVR rate in Danoprevir's group needs to  breakdown based on the genotype.
3- Table 3 is not clear, the numbers of patients with negative RNA at 4W and EOT and SVR12
do not add up to the total number for each group.
Title: Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the
treatment of chronic hepatitis C: the real-world data in China
Version: 0 Date: 03 Jul 2023
Reviewer's report:
This study investigated head-to-head comparison between a well-established DAA HCV
treatment represented by Epclusa vs a newly approved Chinese DAA called Danoprevir. The
authors compared two groups of patients treated with both treatment regimens. There are couple
of issues needs to be addressed:
1- The mode of action of Danoprevir needs to be added in the introduction.
2- The SVR rate in Danoprevir's group needs to  breakdown based on the genotype.
3- Table 3 is not clear, the numbers of patients with negative RNA at 4W and EOT and SVR12
do not add up to the total number for each group.
Please review this paper.
user
Title: Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the
treatment of chronic hepatitis C: the real-world data in China
Version: 0 Date: 03 Jul 2023
Reviewer's report:
This study investigated head-to-head comparison between a well-established DAA HCV
treatment represented by Epclusa vs a newly approved Chinese DAA called Danoprevir. The
authors compared two groups of patients treated with both treatment regimens. There are couple
of issues needs to be addressed:
1- The mode of action of Danoprevir needs to be added in the introduction.
2- The SVR rate in Danoprevir's group needs to  breakdown based on the genotype.
3- Table 3 is not clear, the numbers of patients with negative RNA at 4W and EOT and SVR12
do not add up to the total number for each group.
assistant